Mohammed Khan, MD
Nephrology · Riverside, CANPI 1912008087
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 226 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 13.8% — the pattern of someone who eats at a lot of different presentations.
Across 226 payments — averaging $24.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$764
- Akebia Therapeutics Inc$575
- Travere Therapeutics, Inc.$513
- Otsuka America Pharmaceutical, Inc.$349
- Bayer$310
- OPKO Pharmaceuticals, LLC$305
- plus $3K from 21 others
Across 233 payments — averaging $2905.25 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- CSL Behring$345K
- Akebia Therapeutics Inc$187K
- Bayer$74K
- Merck$25K
- Boehringer Ingelheim$15K
- AstraZeneca$12K
- plus $20K from 4 others
What the payments were for
- Food & beverage$5,490100%
- Education$250%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 34 | $764 |
| Akebia Therapeutics Inc | 30 | $575 |
| Travere Therapeutics, Inc. | 21 | $513 |
| Otsuka America Pharmaceutical, Inc. | 15 | $349 |
| Bayer | 17 | $310 |
| OPKO Pharmaceuticals, LLC | 19 | $305 |
| Ardelyx, Inc. | 15 | $302 |
| Boston Scientific | 4 | $255 |
| Amgen(2 entities) | 9 | $228 |
| GSK | 10 | $228 |
| Aurinia Pharma U.S., Inc. | 9 | $201 |
| Abbott | 1 | $189 |
| Calliditas Therapeutics US Inc. | 7 | $178 |
| Vifor Pharma, Inc. | 7 | $166 |
| Novartis | 6 | $140 |
| Shockwave Medical, Inc | 1 | $137 |
| Boehringer Ingelheim | 5 | $127 |
| Amarin Pharma, Inc. | 1 | $115 |
| Scpharmaceuticals Inc. | 4 | $95 |
| Baxter Healthcare | 1 | $72 |
| Bard Peripheral Vascular, Inc. | 1 | $58 |
| Mallinckrodt Hospital Products Inc. | 2 | $53 |
| CMP Pharma, Inc. | 2 | $52 |
| Fresenius USA Marketing, Inc. | 2 | $39 |
| Alnylam Pharmaceuticals Inc. | 1 | $23 |
| Lilly USA, LLC | 1 | $23 |
| Medtronic | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,514 in reported general payments places this provider in the 80th percentile of 1,341 nephrology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XphozahTenapanor Hcl | 28 | $96,121 |
| VeltassaPatiromer Calcium Sorbitex | 52 | $63,412 |
| AuryxiaFerric Citrate | 23 | $38,925 |
| FarxigaDapagliflozin Propanediol | 41 | $35,991 |
| LokelmaSodium Zirconium Cyclosilicate | 32 | $31,798 |
| RayaldeeCalcifediol | 25 | $30,757 |
| Lanthanum Carbonate | 19 | $28,884 |
| Sevelamer Hcl | 34 | $22,838 |
| ProcritEpoetin Alfa | 19 | $18,825 |
| Sevelamer Carbonate | 151 | $15,520 |
| EliquisApixaban | 18 | $9,767 |
| JanuviaSitagliptin Phosphate | 16 | $8,487 |
| JardianceEmpagliflozin | 11 | $6,320 |
| RetacritEpoetin Alfa-Epbx | 14 | $6,174 |
| Cinacalcet Hcl | 15 | $4,218 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $764 | $67,78973 claims |
| Akebia Therapeutics IncAuryxia | $575 | $38,92523 claims |
| OPKO Pharmaceuticals, LLCRayaldee | $305 | $30,75725 claims |
| Boehringer IngelheimJardiance | $127 | $6,32011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,341 nephrology providers in California.
Other nephrology in Riverside
- Anjay RastogiLos Angeles$2.2M
- Glenn ChertowStanford$2M
- Luis AlvarezPalo Alto$1.8M
- Jose MorfinSacramento$1M
- Rodolfo BatarseRancho Mirage$910K
- Vandana MathurWoodside$769K
- Yasir QaziOrange$618K
- Rafael VillicanaLoma Linda$610K
- Sunil PatelApple Valley$509K
- Suphamai BunnapradistLos Angeles$498K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.